Favipiravir-resistant influenza A virus shows potential for transmission

Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost t...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldhill, Daniel H., Yan, Ada, Frise, Rebecca, Zhou, Jie, Shelley, Jennifer, Gallego Cortés, Ana, Miah, Shahjahan, Akinbami, Omolola, Galiano, Monica, Zambon, Maria, Lackenby, Angie, Barclay, Wendy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195362/
https://www.ncbi.nlm.nih.gov/pubmed/34061908
http://dx.doi.org/10.1371/journal.ppat.1008937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195362/
https://www.ncbi.nlm.nih.gov/pubmed/34061908
http://dx.doi.org/10.1371/journal.ppat.1008937

Ejemplares similares